Spironolactone

Studies of spironolactone in people

7 studies gave spironolactone to people and measured what changed

What changedDesignPeopleSource

up: Increases time in target systolic blood pressure range3% (95% CI −1 to 7%)

Review of trialsfirst year18,823 people pooledBothmean age 72±9 yearsOlder adults; Heart failure with LVEF ≥45%; target systolic blood pressure 110–<130 mmHgESC Congress 2026 abstract, Oct 26, 2026

up: Increases serum potassium

up: Increases discontinuation due to hyperkalemia

Randomized trial72 weeks168 peopleelderlyOlder adults; on irbesartan background therapyThe American journal of the medical sciences, May 20, 2026

no change: Has no effect on health status

Randomized trial9 months527 peopleBothmedian 73 yearsOlder adults; Patient cohortsRevista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, Mar 21, 2026

down: Decreases PICP

Randomized trial9 months488 peopleIn patients at risk of heart failureMedComm, Feb 17, 2026

down: Lowers the risk of mortality10.0 vs. 7.3%, HR 0.68, 95% CI 0.48–0.96

Treated cohortabout 3.3 years1,619 people898 (55.5%) were women, and 721 (44.5%) were men≥70 yearsElderly heart failure patients with preserved ejection fractionFrontiers in cardiovascular medicine, Oct 4, 2021

down: Lowers the risk of mortalityHR 0.68, 95% CI 0.48-0.96

Treated cohort898 peopleWomen≥70 yearsOlder adults; elderly patients with HFpEF (TOPCAT); no significant sex-treatment interaction (p interaction=0.190)Research Square, Feb 23, 2021

no change: Has no effect on peak VO2adjusted mean difference -0.4 mL/kg per minute; 95% CI -1.1-0.4; P = .38

down: Decreases blood pressure

no change: Has no effect on arterial stiffness

Randomized trial9 months71 peopleBoth71 ± 1Older adults; older adults with stable compensated HFpEFJournal of the American Geriatrics Society, May 19, 2017